Abstract
In recent years, we have witnessed a revolution in the treatment of coronary artery disease. The development and improvement of drug eluting stents (DES) have lowered the incidence of restenosis to one-digit figures. In the search for a superior efficacy, animal models have played a key role. The classical swine model of coronary stenting remains the preferred model to measure restenosis, although the rabbit iliac artery stenting has become an accepted alternative. After widespread clinical use of DES, an unforeseen complication arose: late stent thrombosis. In a back-to-bench step, some data from animal models helped to explain the phenomenon. A delayed and incomplete vascular healing was detected. Toxic and hypersensitivity reactions to polymers and/or drugs seem to be the underlying causes. So, translational research focused on the safety aspect of these devices: development of better drug carriers as absorbable polymers or fully bioresorbable scaffolds, selection of different drugs and assessment of the re-endothelialization process. We review and evaluate the efficacy and safety of coronary stents in different animal models. Further improvements in this field such as, the selection of better animal models (e.g. hyperlipidemic, diabetic, atherosclerotic) that closely mimic the clinical setting and longer follow-up periods to detect late complications are also discussed.
Keywords: Animal model, drug eluting stent, endothelium, inflammation, percutaneous coronary intervention, safety, stent thrombosis vascular healing
Current Vascular Pharmacology
Title:Preclinical Evaluation of Coronary Stents: Focus on Safety Issues
Volume: 11 Issue: 1
Author(s): Armando Perez de Prado, Claudia Perez-Martinez, Carlos Cuellas, Jose M. Gonzalo-Orden, Alejandro Diego, Marta Regueiro, Beatriz Martinez-Fernandez, Jose R. Altonaga, J. Francisco G. Marin and Felipe Fernandez-Vazquez
Affiliation:
Keywords: Animal model, drug eluting stent, endothelium, inflammation, percutaneous coronary intervention, safety, stent thrombosis vascular healing
Abstract: In recent years, we have witnessed a revolution in the treatment of coronary artery disease. The development and improvement of drug eluting stents (DES) have lowered the incidence of restenosis to one-digit figures. In the search for a superior efficacy, animal models have played a key role. The classical swine model of coronary stenting remains the preferred model to measure restenosis, although the rabbit iliac artery stenting has become an accepted alternative. After widespread clinical use of DES, an unforeseen complication arose: late stent thrombosis. In a back-to-bench step, some data from animal models helped to explain the phenomenon. A delayed and incomplete vascular healing was detected. Toxic and hypersensitivity reactions to polymers and/or drugs seem to be the underlying causes. So, translational research focused on the safety aspect of these devices: development of better drug carriers as absorbable polymers or fully bioresorbable scaffolds, selection of different drugs and assessment of the re-endothelialization process. We review and evaluate the efficacy and safety of coronary stents in different animal models. Further improvements in this field such as, the selection of better animal models (e.g. hyperlipidemic, diabetic, atherosclerotic) that closely mimic the clinical setting and longer follow-up periods to detect late complications are also discussed.
Export Options
About this article
Cite this article as:
Perez de Prado Armando, Perez-Martinez Claudia, Cuellas Carlos, M. Gonzalo-Orden Jose, Diego Alejandro, Regueiro Marta, Martinez-Fernandez Beatriz, R. Altonaga Jose, Francisco G. Marin J. and Fernandez-Vazquez Felipe, Preclinical Evaluation of Coronary Stents: Focus on Safety Issues, Current Vascular Pharmacology 2013; 11 (1) . https://dx.doi.org/10.2174/1570161111309010074
DOI https://dx.doi.org/10.2174/1570161111309010074 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
Ischemic Cardiovascular Diseases: Mechanisms, Diagnosis and Therapy
Ischemic cardiovascular disease includes myocardial infarction, coronary atherosclerotic heart disease, angina pectoris, etc., constitute the leading cause of patient mortality by preventing tissues from getting sufficient oxygen and nutrients. Ischemic heart disease, as a clinical condition, is characterized by myocardial ischemia, causing an imbalance between myocardial blood supply and demand, ...read more
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Therapeutic Potential of 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibitors for the Treatment of Retinal and Eye Diseases
CNS & Neurological Disorders - Drug Targets Inflammation Theories in Psychotic Disorders: A Critical Review
Infectious Disorders - Drug Targets Potential Phytotherapeutic Approaches for the Treatment of Alzheimer’s Disease: An Overview
Current Traditional Medicine Bioactive Chromone Derivatives – Structural Diversity
Current Bioactive Compounds Metabolic Regulation by the Hexosamine Biosynthesis/O-Linked N-Acetyl Glucosamine Pathway
Current Signal Transduction Therapy Vitamin D and Sepsis: From Associations to Causal Connections
Inflammation & Allergy - Drug Targets (Discontinued) By Passing Microbial Resistance: Xylitol Controls Microorganisms Growth by Means of Its Anti-Adherence Property
Current Pharmaceutical Biotechnology Patent Selections
Recent Patents on Cardiovascular Drug Discovery Mucoadhesivity Characterization of Isabgol Husk Mucilage Microspheres Crosslinked by Glutaraldehyde
Current Drug Delivery The Frequency and Risk Factors of Diabetic Foot Ulcer Recurrence Among Jordanian Patients with Diabetes
Current Diabetes Reviews Pharmacological Treatment of Obesity, Food Intake, and Reversal of Metabolic Disorders
Current Nutrition & Food Science Targeting Chemokine (C-X-C motif) Receptor 3 in Thyroid Autoimmunity
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Impact of Metabolic Surgery on Type-2 Diabetes Remission
Current Diabetes Reviews Protein Misfolding and Aggregation in Alzheimer's Disease and Type 2 Diabetes Mellitus
CNS & Neurological Disorders - Drug Targets Vessel Graft Atherosclerosis in Murine Models
Current Drug Targets Immunomodulatory Actions of Vitamin D Metabolites and their Potential Relevance to Human Lung Disease
Current Respiratory Medicine Reviews <i>Laurus Nobilis</i> Linn. Inhibits Polyol Pathway Enzymes: Strategy for Managing Diabetic Complications
Current Enzyme Inhibition Antagonism of Endothelin (ETA and ETB) Receptors During Renovascular Hypertension-Induced Vascular Dementia Improves Cognition
Current Neurovascular Research Diabetes Therapy: Novel Patents Targeting the Glucose-Induced Insulin Secretion
Recent Patents on DNA & Gene Sequences The Benefits of Exercise and Metabolic Interventions for the Prevention and Early Treatment of Alzheimer's Disease
Current Alzheimer Research